Will findings by Worcester, MA-based Advanced Cell Technologies (ACT) on large-scale blood production from stem cells help the company pull in some much-needed capital? By now you've likely seen reports on a linkurl:paper;http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2008-05-157198v1 appearing today in Blood in which researchers differentiated human embryonic stem cells into oxygen-carrying blood cells, in large quantity. The results suggest it may be possible to create mass quantities of blood for transfusions and blood banks. It's a promising advance in applying embryonic stem cell technology, but what's also interesting about this study is its timing. Just linkurl:last month;http://www.the-scientist.com/blog/display/54884/ ACT stated in a Security and Exchange Commission filing that the biotech did not have funds to stay open through the end of the month. All the press "might help a little" in attracting some new investment to the company, Robert Lanza, chief scientific officer at ACT and senior author on the recent paper, told The Scientist...
Worcester Business JournalBoston Globe
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?